IRAK4 Overview
 Combined Activity of Upstream Biologics (anti-IL-1/18/33/36) in a Pill


                                        • KT-485 has increased            • Learnings from the             • Phase 1 studies of KT-
              KT-485, a second            selectivity and potency over      clinical studies of KT-474       485 are expected to
              generation IRAK4            KT-474 including absence of       will be applied to               initiate in 2026
              degrader, is a highly       any QTc signal and has been       accelerate development
              selective, potent, oral     prioritized for clinical          of KT-485
              IRAK4 degrader              development by Sanofi



    OPPORTUNITY
                                                                                                         Potential to deliver the
• Over 140M potential   • >$55B in combined global    • Large potential for oral degraders               combined activity of
  patient impact1         drug sales2 opportunity       with best-in-pathway efficacy                    upstream biologics in an
                                                        across Th1-Th17 and Th2 Diseases                 oral drug for multiple
                                                                                                         diseases


                   • Partnered with Sanofi                               UPCOMING                • Phase 1 start: 2026
     STATUS                                                              MILESTONES
                   • KT-485 completed IND-enabling studies

                                                                                                                                      51
